SRPT vs. ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, and RDY
Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry.
Sarepta Therapeutics vs.
Sarepta Therapeutics (NASDAQ:SRPT) and argenx (NASDAQ:ARGX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, community ranking, institutional ownership, media sentiment and risk.
Sarepta Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.
86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 60.3% of argenx shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 2.4% of argenx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Sarepta Therapeutics had 31 more articles in the media than argenx. MarketBeat recorded 57 mentions for Sarepta Therapeutics and 26 mentions for argenx. argenx's average media sentiment score of 1.04 beat Sarepta Therapeutics' score of -0.10 indicating that argenx is being referred to more favorably in the news media.
Sarepta Therapeutics received 814 more outperform votes than argenx when rated by MarketBeat users. Likewise, 75.09% of users gave Sarepta Therapeutics an outperform vote while only 67.28% of users gave argenx an outperform vote.
Sarepta Therapeutics has a net margin of 7.43% compared to argenx's net margin of -2.11%. Sarepta Therapeutics' return on equity of 11.00% beat argenx's return on equity.
Sarepta Therapeutics currently has a consensus price target of $167.41, suggesting a potential upside of 119.32%. argenx has a consensus price target of $687.00, suggesting a potential upside of 13.00%. Given Sarepta Therapeutics' higher possible upside, equities research analysts clearly believe Sarepta Therapeutics is more favorable than argenx.
argenx has higher revenue and earnings than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.
Summary
Sarepta Therapeutics beats argenx on 11 of the 18 factors compared between the two stocks.
Get Sarepta Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sarepta Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SRPT) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy SRPT Stock Free SRPT Stock Alerts